Table 1 Characterization of the patient cohort

Gender; female/male

8/10

18/23

0.595

7/7

11/16

0.406

1/2

5/4

0.100

0/1

2/3

–

Age at onset, years; mean (95% Cl)

41.88 (33–50)

37.61 (32–42)

0.356

35.28 (27–42)

34.22 (28–40)

0.823

63.33 (48–78)

52.88 (43–62)

0.190

70 (/)

28.40 (19–37)

–

From onset to diagnosis, days; median (IQR)

20 (78)

24 (52)

0.863

14.5 (23.75)

16 (51)

0.185

35 (/)

60 (63)

0.864

190 (/)

31 (41)

–

Follow-up duration, days; mean (95% Cl)

1058 (768–1349)

1362 (1136–1587)

0.120

1084 (802–1376)

1488 (1215–1556)

0.059

1086 (/)

1640 (1278)

0.926

244 (/)

561 (640)

–

Symptoms; n (%)

 Seizures

66.7%

61.0%

0.455

71.4%

66.7%

0.100

66.7%

55.6%

0.100

0.00%

40%

–

 Cognitive impairment

94.4%

85.4%

0.422

92.9%

85.2%

0.645

100%

100%

–

100%

60%

–

 Psychiatric symptoms

83.3%

87.8%

0.690

78.6%

88.9%

0.393

100%

88.9%

0.100

100%

80%

–

 Decreased consciousness

44.4%

29.3%

0.201

57.1%

33.3%

0.189

0.0%

11.1%

0.100

0.0%

40%

–

 Autonomic dysfunction

27.8%

22.0%

0.742

28.6%

25.9%

.0.100

33.3%

0.0%

0.250

0.0%

40%

–

 Movement disorder

44.4%

26.8%

0.151

50%

22.2%

0.089

33.3%

33.3%

0.100

0.0%

40%

–

 Fever

44.4%

39.0%

0.457

57.1%

51.9%

0.504

0.0%

11.1%

0.100

0.0%

20%

–

CSF/MRI/EEG profiles

 CSF cc; median, (IQR)

7 (67)

8 (23)

0.613

8.5 (90.5)

12 (26)

0.264

4 (/)

2 (4)

0.282

2 (/)

1 (62)

 CSF protein; mean, (95% Cl)

404.45 (318–490)

353.82 (288–419)

0.370

372.05 (274–469)

405.57 (313–497)

0.637

470.28 (93–847)

247.21 (179–314)

0.009

660.7 (/)

266.32 (144–387)

–

 CSF pressure; mean, (95% Cl)

174.72 (146–203)

161.46 (140–182)

0.463

182.85 (147–218)

170.18 (140–199)

0.587

145.00 (46–243)

131.66 (100–162)

0.632

150 (/)

168.00 (121–214)

–

 MRI abnormalities; n (%)

50.0%

56.1%

0.440

64.3%

51.9%

0.336

0.0%

77.8%

0.045

0.0%

40%

–

 EEG abnormalities; n (%)

61.1%

43.9%

0.175

71.4%

48.1%

0.137

33.3%

33.3%

0.100

0.0%

40%

–

CSF/Serum Ab profiles

 CSF Ab positive

94.4%

80.5%

0.252

100%

88.9%

0.539

100%

77.8%

0.100

0.0%

40%

–

 Serum Ab positive

38.9%

61.0%

0.100

28.6%

48.1%

0.321

66.7%

77.8%

0.100

100%

100%

–

 Both Ab positive

33.3%

41.5%

0.386

28.6%

37.0%

0.734

66.7%

55.6%

0.100

0.0%

40%

–

 Prior 1st-line immunotherapy; n (%)

100%

100%

–

100%

100%

–

100%

100%

–

100%

100%

–

1st-line therapy, n (%)

–

 MPPT

72.2%

97.6%

0.008

85.7%

93.3%

0.265

33.3%

100%

0.045

0

100%

–

 IVIG

94.4%

46.3%

 <  .0001

92.9%

55.6%

0.031

100%

33.3%

0.182

100%

20%

–

 Both

66.7%

43.9%

0.092

78.6%

51.9%

0.176

33.3%

33.3%

0.100

0

20%

–

RTX therapy

 Time from RTX therapy, days; median (IQR)

74.5 (410)

–

–

128.5 (405)

–

–

6 (/)

–

–

5 (/)

–

–

 No. of RTX infusions, n; median (IQR)

5 (4)

–

–

5 (3)

–

–

3 (/)

–

–

3 (/)

–

–

 Cumulative RTX dose, g; median (IQR)

500 (400)

–

–

500 (300)

–

–

300 (/)

–

–

300 (/)

–

–

 1st to last infusion, days; median (IQR)

389 (864)

–

–

457.5 (863)

–

–

15 (/)

–

–

214 (/)

–

–

 Averaged dose of prednisone, mg/day; median (IQR)

4.375 (7.67)

27.13 (21.67)

 <  .0001

5.563 (4.011)

28.89 (21.67)

 <  .0001

0

10.83 (19.52)

0.009

0

25.71 (20.057)

–

Relapses; n (%)

 After 1st-line therapy

33.3%

12.2%

0.074

42.9%

18.5%

0.140

33.3%

0.0%

0.250

0

0

–

 After RTX therapy

0

–

–

0

–

–

0

–

–

0

–

–